Resources with keywords: poxvirus



First Clade Ib Monkeypox Virus Infection Reported in the Americas — California, November 2024
CDC / MMWR
13 February 2025

Levy V, Branzuela A, Hsieh K, et al.
The first reported clade Ib MPXV infection in the Americas was identified via electronic laboratory reporting in California in a U.S. traveler who returned from East Africa.

Wastewater Monitoring Dashboard for Canada (NEW 1/11, Website, Regulatory)
Governement of Canada- National Collaboration Centre for Infectious Diseases

This dashboard provides data about COVID-19, flu, RSV and mpox virus levels in wastewater.

First Case of Clade I Mpox Diagnosed in the United States
CDC / Health Alert Network (HAN)
18 November 2024

On November 18, 2024, the U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory about the first case of clade I mpox diagnosed in the United States.

WHO grants approval for use of Bavarian Nordic’s mpox vaccine in adolescents
World Health Organization (WHO)
16 October 2024

A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox

Risk to United States from clade I mpox outbreak in Central and Eastern Africa
CDC
14 November 2024

CDC assessed the risk to the United States posed by the clade I mpox outbreak in the Democratic Republic of Congo and in countries in Central and Eastern Africa. Four travel-associated cases of clade Ib mpox have been confirmed in the United States—in California, Georgia, New Hampshire, and New York. Our risk assessment remains unchanged, since onward spread of clade I mpox has not occurred in the United States to date. The risk to the general population is assessed as low.

Clade I Mpox in Children in Africa and Expectations for Transmission in the United States
CDC
17 October 2024

The high proportion of children with suspected mpox reported in the current outbreak is likely due to a number of factors, including spread within and between close households, younger population demographics in impacted countries, misdiagnosis of other diseases (such as measles), poor sanitary conditions, limited access to health services, and a high level of food insecurity and malnutrition.

Mpox vaccine is safe and generates a robust antibody response in adolescents
NIH
16 October 2024

MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic.

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024
CDC / MMWR
10 October 2024

Gigante CM, Takakuwa J, McGrath D, et al.
Tecovirimat is the first-line drug for treatment of orthopoxvirus infection (e.g., smallpox and mpox). Viral mutations that render the drug ineffective can develop during treatment.

Prevention Strategies for Mpox, including Vaccinating People at Risk via Sexual Exposure, for U.S. Travelers Visiting Countries with Clade I Mpox Outbreaks
CDC / Health Alert Network (HAN)
23 September 2024

This is a Health Alert Network (HAN) Health Update to provide additional information about the ongoing outbreak of clade I monkeypox virus (MPXV), the virus that causes mpox, in Central and Eastern Africa

Information For Healthcare Professionals
FDA

Includes recommendations for vaccination of health care workers, specimen collection and infection control.

Go to Top